<DOC>
	<DOC>NCT00746824</DOC>
	<brief_summary>The purpose of this study is to determine the effects of TM30339 on weight loss in obese individuals after 28 days dosing.</brief_summary>
	<brief_title>A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.</brief_title>
	<detailed_description>Obesity is a disease with large socioeconomic consequences and many serious health consequences including Type 2 diabetes, dyslipidemia and cardiovascular diseases. The prevalence of obesity is increasing both in developed and developing countries. There is a great need for further medicinal treatments that effectively will support life style changes or surgical procedures in reducing or maintaining bodyweight. 7TM Pharma has identified TM30339 as a clinical development candidate molecule with potential to assist in the control and amelioration of obesity in humans.</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>1. Obese males and females with a BMI of 3040 kg/m2 inclusive and weight in the range of 85 135 kg inclusive 2. Age 1860 years inclusive 3. Stable lifestyle e.g. smoking, exercise and eating patterns and times for at least 6 months, and willing to maintain these habits during the course of the study 4. Stable weight over past 2 months i.e. a change in body weight &lt; 3 kg as reported by the subject 1. Subjects with a history of allergies toward products containing natural rubber (e.g. latex) 2. Subjects with, or with a history of, any clinically significant neurological, gastrointestinal (including bariatric surgery), renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, or other major disorders 3. Subjects who have a supine blood pressure at screening or Visit 1 higher than 150/95 mmHg by repeat measurements within 15 minutes 4. Subjects who have a QTc (Bazett's correction) interval of &gt; 450 msec at screening 5. Subjects with bradycardia (heart rate &lt; 50) 6. Subjects with heart block 7. Clinically significant thyroid dysfunction as evidenced by TSH &gt; 1.5 X ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>7TM Pharma</keyword>
	<keyword>TM30339</keyword>
	<keyword>Y4 receptor antagonist</keyword>
</DOC>